Publication

A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland

Journal Paper/Review - Mar 21, 2021

Barbier Michaela Carla, Pardo Esther, Panje Cédric, Gautschi Oliver, Lupatsch Judith Eva, Swiss Group for Clinical Cancer Research (SAKK)